www.fdanews.com/articles/197551-promega-gets-ce-mark-for-solid-tumor-diagnostic
Promega Gets CE Mark for Solid Tumor Diagnostic
June 10, 2020
Wisconsin-based Promega has earned a CE mark for its OncoMate MSI Dx analysis system for detecting microsatellite instability (MSI) in solid tumors.
MSI biomarkers can be used to predict a patient’s response to immune-oncology therapies for certain cancers.
“Screening cancer patients with these reliable markers” can help guide care and treatment decisions, the company said.